Oliver Langford

1.0k total citations · 1 hit paper
27 papers, 579 citations indexed

About

Oliver Langford is a scholar working on Psychiatry and Mental health, Physiology and Economics and Econometrics. According to data from OpenAlex, Oliver Langford has authored 27 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Psychiatry and Mental health, 10 papers in Physiology and 10 papers in Economics and Econometrics. Recurrent topics in Oliver Langford's work include Dementia and Cognitive Impairment Research (15 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Alzheimer's disease research and treatments (9 papers). Oliver Langford is often cited by papers focused on Dementia and Cognitive Impairment Research (15 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Alzheimer's disease research and treatments (9 papers). Oliver Langford collaborates with scholars based in United States, United Kingdom and Netherlands. Oliver Langford's co-authors include Paul Aisen, Rema Raman, Reisa A. Sperling, Gustavo Jimenez‐Maggiora, Michael Donohue, Richard Stevens, Jeffrey K Aronson, Joshua D. Grill, Ting Cai and James P Sheppard and has published in prestigious journals such as Neurology, The British Journal of Psychiatry and BMJ.

In The Last Decade

Oliver Langford

24 papers receiving 572 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses

2021 140 citations Ting Cai, Lucy Abel et al. BMJ profile →

Peers

Oliver Langford

PMH

PHYSI

SURGE

PHEOH

Douglas Barthold United States

Dawn Farrell Ireland

Miriam L. Zichlin United States

Miriam L. Haaksma Netherlands

Andrew D. Mosholder United States

Camilla Prete Italy

V. Gilleron France

Francesca Nicosia United States

Kent H. Summers United States

Flávia Mayer Italy

Douglas Barthold United States

Oliver Langford

184 ×0.7

PMH

143 ×0.9

PHYSI

118 ×0.9

143 ×1.7

SURGE

61 ×0.8

PHEOH

Citations per year, relative to Oliver Langford Oliver Langford (= 1×) peers Douglas Barthold

Countries citing papers authored by Oliver Langford

Since Specialization

Citations

This map shows the geographic impact of Oliver Langford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Langford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Langford more than expected).

Fields of papers citing papers by Oliver Langford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Langford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Langford. The network helps show where Oliver Langford may publish in the future.

Co-authorship network of co-authors of Oliver Langford

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Langford. A scholar is included among the top collaborators of Oliver Langford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Langford. Oliver Langford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ritchie, Marina, Oliver Langford, Michael Donohue, et al.. (2025). Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites. Alzheimer s Research & Therapy. 17(1). 222–222.

Donohue, Michael, Oliver Langford, Rema Raman, et al.. (2025). Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid. Neurology. 104(12). e213775–e213775. 1 indexed citations

Insel, Philip S., Niklas Mattsson, Oliver Langford, et al.. (2025). Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease. JAMA Neurology. 82(10). 985–985. 3 indexed citations

Raman, Rema, Andy Liu, Oliver Langford, et al.. (2024). Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimer s & Dementia. 20(6). 3827–3838. 18 indexed citations

Langford, Oliver, Rema Raman, Paul Aisen, et al.. (2024). Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4. The Journal of Prevention of Alzheimer s Disease. 11(4). 831–837. 5 indexed citations

Raman, Rema, Michael Donohue, Karin Ernström, et al.. (2024). Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial. The Journal of Prevention of Alzheimer s Disease. 11(4). 874–880. 2 indexed citations

Sperling, Reisa A., Michael Donohue, Robert A. Rissman, et al.. (2024). Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies. The Journal of Prevention of Alzheimer s Disease. 11(4). 802–813. 24 indexed citations

Rissman, Robert A., Oliver Langford, Rema Raman, et al.. (2024). Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(4). 823–830. 14 indexed citations

Winston, Charisse N., Oliver Langford, Rema Raman, et al.. (2023). Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. Journal of Alzheimer s Disease. 92(1). 95–107. 10 indexed citations

10.

Rissman, Robert A., Oliver Langford, Rema Raman, et al.. (2023). Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer s & Dementia. 20(2). 1214–1224. 64 indexed citations

11.

Donohue, Michael, Oliver Langford, Philip S. Insel, et al.. (2023). Natural cubic splines for the analysis of Alzheimer's clinical trials. Pharmaceutical Statistics. 22(3). 508–519. 9 indexed citations

12.

Raman, Rema, Oliver Langford, Keith A. Johnson, et al.. (2023). Racial and Ethnic Differences in Plasma Biomarker Eligibility in a Preclinical Alzheimer’s Disease Trial. Alzheimer s & Dementia. 19(S24). 1 indexed citations

13.

Cai, Ting, Lucy Abel, Oliver Langford, et al.. (2021). Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 374. n1537–n1537. 140 indexed citations breakdown →

14.

Sato, Kenichiro, Ryoko Ihara, Kazushi Suzuki, et al.. (2021). Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study. Alzheimer s & Dementia Translational Research & Clinical Interventions. 7(1). 18 indexed citations

15.

Walter, Sarah, Taylor Clanton, Oliver Langford, et al.. (2020). Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD). The Journal of Prevention of Alzheimer s Disease. 7(4). 219–225. 26 indexed citations

16.

Jimenez‐Maggiora, Gustavo, Rema Raman, Oliver Langford, et al.. (2020). TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. The Journal of Prevention of Alzheimer s Disease. 7(4). 226–233. 14 indexed citations

17.

Langford, Oliver, Rema Raman, Reisa A. Sperling, et al.. (2020). Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. The Journal of Prevention of Alzheimer s Disease. 7(4). 213–218. 32 indexed citations

18.

Walter, Sarah, Oliver Langford, Taylor Clanton, et al.. (2020). The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years. The Journal of Prevention of Alzheimer s Disease. 7(4). 234–241. 14 indexed citations

19.

Aisen, Paul, Reisa A. Sperling, Jeffrey L. Cummings, et al.. (2020). The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview. The Journal of Prevention of Alzheimer s Disease. 7(4). 208–212. 25 indexed citations

20.

Burns, Tom, et al.. (2015). A randomised controlled trial of time-limited individual placement and support: IPS-LITE trial. The British Journal of Psychiatry. 207(4). 351–356. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact